Clinical Trial

Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors

Name: Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors — clinical trial record (NCT07259889)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and immunogenicity of CEL001 injection in the treatment of advanced solid tumors.

Trial Details

NCT Number	NCT07259889
Lead Sponsor	Guangzhou Xiling Biotechnology Co., Ltd.
Conditions	Advanced Solid Tumors (Phase 1)
Enrollment	13 participants
Start Date	2025-06-16
Primary Completion	2028-06-15 (estimated)
Study Completion	2028-06-15 (estimated)
Updated on ClinicalTrials.gov	2025-12-02